Inferring Multi-Organ Genetic Causal Connections using Imaging and Clinical Data through Mendelian Randomization

3

4 Running title: MR atlas for multi-organ images

- 5
- 6 Juan Shu¹, Rong Zheng², Julio Chirinos^{3,4}, Carlos Copana¹, Bingxuan Li⁵, Zirui Fan⁶,
- 7 Xiaochen Yang¹, Yilin Yang⁷, Xiyao Wang⁸, Yujue Li¹, Bowei Xi¹, Tengfei Li^{9,10}, Hongtu Zhu¹¹⁻

8 ^{14*}, and Bingxin Zhao^{1,6,15-19*#}

- 9
- ¹Department of Statistics, Purdue University, West Lafayette, IN 47907, USA.
- ¹¹ ²Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, Shanxi
- 12 030001, China.
- 13 ³Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
- 14 19104, USA.
- ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
- 16 ⁵UCLA Samueli School of Engineering, Los Angeles, CA 90095, USA.
- 17 ⁶Department of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA 19104,
- 18 USA.

19 ⁷Department of Computer and Information Science and Electrical and Systems Engineering,

- 20 School of Engineering & Applied Science, University of Pennsylvania, Philadelphia, PA 19104,
- 21 USA.
- ⁸Department of Computer Science, Purdue University, West Lafayette, IN 47907, USA.
- ⁹Department of Radiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- ¹⁰Biomedical Research Imaging Center, School of Medicine, University of North Carolina at Chapel
- 25 Hill, Chapel Hill, NC 27599, USA.
- ²⁶ ¹¹Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599,
- 27 USA.
- ¹²Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- ¹³Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 30 27599, USA.
- 31 ¹⁴Department of Statistics and Operations Research, University of North Carolina at Chapel Hill,
- 32 Chapel Hill, NC 27599, USA.

- 1 ¹⁵Applied Mathematics and Computational Science Graduate Group, University of Pennsylvania,
- 2 Philadelphia, PA 19104, USA.
- 3 ¹⁶Center for AI and Data Science for Integrated Diagnostics, Perelman School of Medicine,
- 4 University of Pennsylvania, Philadelphia, PA 19104, USA.
- 5 ¹⁷Penn Institute for Biomedical Informatics, Perelman School of Medicine, University of
- 6 Pennsylvania, Philadelphia, PA 19104, USA.
- ¹⁸Population Aging Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
- 8 ¹⁹Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia,
- 9 PA 19104, USA.
- 10
- 11 **Corresponding authors*:
- 12 Hongtu Zhu (<u>htzhu@email.unc.edu</u>) and Bingxin Zhao (<u>bxzhao@upenn.edu</u>)
- 13
- 14 *#Lead contact:*
- 15 Bingxin Zhao
- 16 413 Academic Research Building
- 17 265 South 37th Street, Philadelphia, PA 19104.
- 18 E-mail: <u>bxzhao@upenn.edu</u> Phone: (215) 898-8222

1 Abstract

2 Understanding the complex causal relationships among major clinical outcomes and the 3 causal interplay among multiple organs remains a significant challenge. By using imaging 4 phenotypes, we can characterize the functional and structural architecture of major 5 human organs. Mendelian randomization (MR) provides a valuable framework for 6 inferring causality by leveraging genetic variants as instrumental variables. In this study, 7 we conducted a systematic multi-organ MR analysis involving 402 imaging traits and 372 8 clinical outcomes. Our analysis revealed 184 genetic causal links for 58 diseases and 56 9 imaging traits across various organs, tissues, and systems, including the brain, heart, liver, 10 kidney, lung, pancreas, spleen, adipose tissue, and skeletal system. We identified intra-11 organ causal connections, such as the bidirectional genetic links between Alzheimer's 12 disease and brain function, as well as inter-organ causal effects, such as the impact of 13 heart diseases on brain health. Metabolic disorders, such as diabetes, exhibited causal 14 effects across multiple organs. These findings shed light on the genetic causal links 15 spanning multiple organs, providing insights into the intricate relationships between 16 organ functions and clinical outcomes.

17

18 **Keywords**: Abdominal MRI; Brain MRI; Cardiovascular MRI; Clinical outcomes; FinnGen;

19 GWAS; Mendelian randomization; Skeleton DXA; UK Biobank.

1 Medical imaging techniques such as magnetic resonance imaging (MRI) provide important 2 information about the structure and function of many human organs, such as the brain, 3 heart, liver, and kidney. Their derived imaging traits have found widespread use in both 4 clinical research and practical applications. For example, structural and functional imaging 5 traits extracted from brain MRIs have consistently revealed abnormalities associated with 6 Alzheimer's disease, particularly within the hippocampal region¹. Cardiovascular MRI 7 (CMR) provides quantitative data regarding ventricular function, cardiovascular structure, 8 and myocardial perfusion, all of which are intricately linked to cardiovascular diseases². 9 Furthermore, skeletal dual-energy X-ray absorptiometry (DXA) aids in identifying novel 10 genetic variants that influence the human skeletal structure, thereby revealing significant 11 evolutionary trends in human anatomical changes leading to pathogenesis³. Several large-12 scale organ imaging datasets (on the scale of over 10,000 participants) have recently been 13 made publicly available, revealing details about human organ structure and function⁴⁻⁸. A 14 large number of complex traits and clinical outcomes have been found to associate with 15 organ imaging traits in these population-based studies^{9,10}.

16

17 Despite these advances, inherent limitations in observational data pose challenges in 18 definitively establishing causal relationships between imaging traits and clinical outcomes, 19 as well as in gaining a comprehensive understanding of the causal interplay across various 20 organs¹¹. Mendelian randomization (MR) uses genetic variants as instrumental variables to infer causality from observational data^{12,13}. Operating under certain assumptions 21 22 regarding genetic, exposure, and outcome variables, MR is an epidemiological tool to 23 uncover causal relationships between exposure and outcome variables, while controlling 24 for confounding factors. Both family and population-based studies have demonstrated 25 that numerous imaging traits and complex diseases are profoundly influenced by genetics. 26 Hundreds of associated genetic loci have been pinpointed in large-scale genome-wide association studies (GWAS)^{3,8,14-28}. Using these GWAS summary-level data (summary 27 28 statistics), MR methods can unveil causal relationships between imaging measurements 29 and clinical outcomes. Numerous recent MR studies have explored the genetic causality of imaging traits^{11,29-34}. However, a common limitation of these MR studies is their focus 30 31 on a single organ (or imaging modality) and/or a single disease, or diseases in a specific 32 domain, such as brain imaging and psychiatric disorders²⁹. It is crucial to note, however,

that many diseases act as the causes and/or consequences of functional and structural changes in various organs of the human body^{35,36}. Cross-organ analysis can elucidate the complexity of human physiology and holds great potential to improve our understanding of a multitude of diseases, ultimately enhancing our strategies for their diagnosis, treatment and prevention. Consequently, it is essential to conduct MR analysis from a multi-organ perspective to comprehend the clinical implications of imaging traits amidst the complex interrelationships of organ systems.

8

9 In this paper, we carried out a systematic two-sample MR analysis to explore the causal 10 relationships between multi-organ imaging and clinical endpoints. We consolidated 11 GWAS summary statistics from 402 multi-organ imaging traits (with an average sample 12 size $n \approx 35,000$) from the UK Biobank (UKB)³⁷ study along with 372 clinical outcomes (304) 13 with more than 10,000 cases and 68 more with at least 5000 cases) sourced from the 14 FinnGen project²⁷ (Tables S1-S2). Our focus was on three major brain MRI modalities: 1) 101 regional brain volumes²¹ from structural MRI (sMRI); 2) 110 diffusion tensor imaging 15 (DTI) parameters²³ from diffusion MRI (dMRI); and 3) 90 functional activity (amplitude³⁸) 16 17 and connectivity traits from functional MRI (fMRI)²⁵. Furthermore, we incorporated 82 18 CMR traits extracted from short-axis, long-axis, and aortic cine cardiac MRI^{39,40}. We also 19 considered 11 abdominal MRI traits, measuring volume, fat, or iron content in seven 20 organs and tissues⁸, and eight DXA imaging traits that gauged the lengths of all long bones and the width of the hip and shoulder³. We applied 8 MR methods⁴¹⁻⁴⁹ to investigate 21 22 bidirectional genetic causal links. The study design is presented in Figure 1A, while Figure 23 **1B** offers a high-level summary of our key findings. Additional details on these multi-organ 24 imaging traits are provided in the **Methods** section.

25

26 **RESULTS**

27 Genetic causality between brain imaging and multi-organ diseases

We explored the causal relationship between brain imaging traits and multi-organ diseases. At a false discovery rate (FDR) 5% level ($P < 1.31 \times 10^{-4}$, adjusting for multiple testing for both directions), MR identified 33 significant genetic causal effects of 6 diseases (within 4 major categories) on 6 brain imaging traits. These categories included diseases of the nervous system, diseases of the circulatory system, diseases marked as

autoimmune origin, and diseases of the digestive system. Among these 33 significant
 findings, 14 were associated with hypertension (9 with hypertension and 5 with essential
 hypertension), 12 with Alzheimer's disease and dementia, 5 with autoimmune diseases,
 1 with allergic asthma, and 1 with atrial fibrillation (Table S3).

5

6 Our results revealed that neurodegenerative conditions, including dementia and 7 Alzheimer's disease, could potentially impair functional activity across various networks. 8 Specifically, dementia and Alzheimer's disease were consistently found to compromise 9 the integrity of the default mode (β < -0.09, P < 2.19×10⁻⁵, >6/8 MR methods significant), 10 dorsal-attention (β < -0.05, P < 2.24×10⁻⁵, >5/8 MR methods significant), and 11 frontoparietal networks (β < -0.03, P < 4.53×10⁻⁵, >5/8 MR methods significant) (Fig. 2A). 12 In addition to degenerative neurological diseases, we consistently observed causal effects of hypertension on regional brain volume, fMRI traits, and DTI parameters. For example, 13 14 hypertension had negative causal effects on grev matter volume ($\beta < -0.03$, $P < 1.30 \times 10^{-1}$ 15 ¹⁰, 5/8 MR methods significant). Similarly, a potential negative effect of hypertension was 16 observed on the fractional anisotropy (FA) of the body of the corpus callosum tract (BCC, 17 β <-0.07, P<1.12×10⁻⁶, 6/8 MR methods significant) and the genu of the corpus callosum 18 (GCC, β < -0.01, *P* < 2.29×10⁻⁵, 6/8 MR methods significant). Conversely, positive effects 19 were found on other DTI parameters, such as axial diffusivity (AD), mean diffusivity (MD) 20 and radial diffusivity (RD) of superior corona radiata (SCR), RD of BCC, as well as RD of 21 GCC (β > 0.01, P < 4.30×10⁻⁵, 6/8 MR methods significant). It makes sense as lower MD 22 and higher FA values typically indicating better white matter health⁵⁰. In addition, we 23 observed that hypertension was causally related to decreased functional connectivity of 24 the orbito-affective network (β > -0.05, P < 1.16×10⁻⁵, 6/8 MR methods significant) (**Fig.** 25 **2B**). Autoimmune diseases were mostly found to affect DTI parameters, such as the AD 26 and MD of SCR (β < -0.04, P < 9.43×10⁻⁵, >5/8 MR methods significant) (**Fig. 2C**).

27

Brain and other organ-related diseases may also be affected by structural or functional changes in the brain. To investigate this, we used brain imaging traits as exposure variables and clinical endpoints as the outcome variables. At an FDR 5% level ($P < 1.31 \times 10^{-10}$ 4), we identified 12 significant relationships between 5 brain imaging traits and 3 types of clinical endpoints (**Table S3**). Most of the significant imaging-disease pairs were related

to DTI parameters and the majority of the significant findings pertained to brain diseases (11/12). For example, we found that the RD of BCC and GCC was causally related to dementia ($\beta < -0.31$, $P < 1.47 \times 10^{-5}$, >5/8 MR methods significant), and the FA of SCR was associated with an increased risk of Alzheimer's disease ($\beta > 0.33$, $P < 6.24 \times 10^{-5}$, 7/8 MR methods significant) (**Fig. 2D**).

6

7 Causal genetic relationships between CMR traits and clinical outcomes

8 We assessed the potential causal effects from clinical endpoints to CMR measures of 9 heart structure and function. We identified 137 significant results at an FDR 5% level (P < 10 6.95×10⁻⁴), including 44 unique CMR traits of the ascending aorta (AAo), descending aorta 11 (Dao), left atrium (LA), right ventricle (RV), and left ventricle (LV). These significant causal 12 effects were identified in 20 unique clinical endpoints of 5 categories: diseases of the 13 circulatory system (10/20), endocrine, nutritional and metabolic diseases (6/20), mental 14 and behavioral disorders (2/20), diseases of eye and adnexa (1/20), as well as neoplasms 15 (ICD2 & ICD-O-3, 1/20). Among the 137 significant findings, 117 were associated with 16 heart-related diseases (114 diseases of the circulatory system and 3 cardiac arrhythmias), 17 15 with endocrine, nutritional and metabolic diseases, and 3 with mental and behavioral 18 disorders (Table S4).

19

20 Causal effects of hypertension were widely observed on many LV traits, such as global 21 and regional⁵¹ myocardial-wall thickness (segments 1-16, β > 0.07, P < 6.44×10⁻⁵, 7/8 MR 22 methods significant) and radial strain traits (segments 7-9 and 12-15, β > 0.06, P < 23 8.14×10⁻⁵, 7/8 MR methods significant). In addition to LV traits, hypertension also 24 affected multiple other CMR traits. For example, it had negative causal impacts on Aao 25 and Dao distensibility⁵²⁻⁵⁴ (β < -0.10, P < 2.11×10⁻⁵, 7/8 MR methods significant), as well 26 as positive effects on AAo and Dao minimum/maximum areas (AAo_{max} and AAo_{min} areas, 27 β > 0.10, P < 3.32×10⁻⁶, 7/8 MR methods significant). The causal effects were also 28 observed in several LA traits, such as negative effects on the left atrium ejection fraction 29 $(\beta < -0.07, P < 4.45 \times 10^{-4}, 7/8$ MR methods significant) as well as positive effects on left atrium minimum/maximum volumes (LA_{min} and LA_{max} volumes, β > 0.06, P < 4.72×10⁻⁴, 30 31 6/8 MR methods significant). Similar to hypertension, we found that cardiovascular 32 diseases and hypertensive diseases had causal effects on various LV traits, such as

1 regional myocardial-wall thickness, left ventricular myocardial mass, and regional radial 2 strain. We further identified heart-related disorders that contributed to alterations in 3 heart structure and function. Conditions such as atrial fibrillation and flutter, heart failure, 4 and cardiac arrhythmias were primarily linked to LA traits, including negative effects on 5 the left atrium ejection fraction (β < -0.07, P < 1.35×10⁻⁵, 7/8 MR methods significant) and 6 positive effects on LA_{min} and LA_{max} volumes (β > 0.07, P < 1.08×10⁻⁶, 7/8 MR methods 7 significant) (**Fig. 3A**).

8

9 We also observed causal effects of other diseases, such as endocrine, nutritional and 10 metabolic disorders, on heart structure and function. For example, diabetes was observed 11 to have negative effects on regional longitudinal strain (segment 2, $|\beta| > 0.03$, $P < 1.68 \times 10^{-1}$ 12 ⁴, 5/8 MR methods significant) and positive effects on right ventricular ejection fraction $(\beta > 0.04, P < 1.73 \times 10^{-4}, 5/8$ MR methods significant). Additionally, type 2 diabetes led to 13 14 a lower level of AAo_{max} and AAo_{min} areas (β < -0.04, P < 3.53×10⁻⁴, 5/8 MR methods 15 significant) and larger global and regional myocardial-wall thickness (segments 5-6 and 16 10-12, $\beta > 0.03$, $P < 5.35 \times 10^{-4}$, 5/8 MR methods significant). Pure hypercholesterolemia 17 and other metabolic disorders were causally linked to an enlarged left atrium stroke 18 volume (β > 0.05, *P* < 3.31×10⁻⁴, 5/8 MR methods significant). Moreover, hypothyroidism 19 negatively affected regional radial strain (segment 12, β < -0.05, P < 3.31×10⁻⁴, 5/8 MR 20 methods significant) (Fig. 3B). It is also noteworthy that we found evidence suggestive of 21 causality for brain disorders on heart phenotypes, such as a potential causal effect of 22 dementia on right ventricular end-diastolic volume ($\beta > 0.03$, $P < 2.42 \times 10^{-4}$, 5/8 MR 23 methods significant), as well as mood disorders on regional myocardial-wall thickness 24 (segments 8 and 12, β < -0.12, *P* < 4.81×10⁻⁴, 5/8 MR methods significant) (**Fig. 3C**).

25

Structural and functional abnormalities within the heart may also increase the risk of multi-organ diseases, considering the role of the heart in pumping blood to all other organs⁵⁵. We examined this direction by treating CMR traits as exposure variables and clinical endpoints as the outcomes. At an FDR 5% level ($P < 6.95 \times 10^{-4}$), we identified 20 significant causal pairs, with most related to heart-related diseases and a small portion to diseases of the nervous system. Some of these examples correspond to well-known relationships. For example, larger left ventricular ejection fraction was consistently found

1 to reduce the risk of heart failure (β < -0.30, *P* < 2.38×10⁻⁴, 5/8 MR methods significant).

2 (Fig. 3D). We also found that CMR traits, such as regional myocardial-wall thickness

3 (segment 5), had causal effects on Alzheimer's disease (β < -0.60, P < 4.85×10⁻⁴, 5/8 MR

- 4 methods significant) (Fig. 3E).
- 5

6 Causal genetic links between abdominal imaging traits and clinical outcomes

7 We first examined the causal effects of multi-organ diseases on abdominal imaging traits, 8 including the volume or iron content of organs like the spleen, kidney, liver, lung, and 9 pancreas⁸. At an FDR 5% level ($P < 1.40 \times 10^{-3}$), we identified 62 significant causal 10 relationships between multi-organ diseases and abdominal imaging traits, after excluding 11 straightforward associations such as the link between obesity and both adipose tissue 12 volume and abdominal organ fat content. Notably, liver imaging traits constituted the 13 majority of these findings (34/62). Brain disorders were the most prevalent among the 14 significant relationships identified (23/62, mental and behavioral disorders (14) and 15 diseases of the nervous system (9)), followed by endocrine, nutritional and metabolic 16 diseases (18/62) (Table S5). These findings aligned with ongoing research on the complex 17 interplay between the brain and abdominal organs, such as the brain-gut connection⁵⁶⁻⁵⁸, brain-kidney connection^{59,60}, and brain-liver connection⁶¹. Specifically, Alzheimer's 18 19 disease and dementia were linked to a reduction in liver volume and percent of liver fat 20 $(|\beta| > 0.02, P < 1.28 \times 10^{-4}, 6/8$ MR methods significant). Sleep appear was observed to 21 positively influence the liver volume and the volume of abdominal subcutaneous adipose 22 tissue ($\beta > 0.19$, $P < 9.61 \times 10^{-4}$, 6/8 MR methods significant). Furthermore, alcohol use 23 disorder was associated with an increase in percent liver fat ($\beta > 0.13$, $P < 2.09 \times 10^{-5}$, 6/8 24 MR methods significant). In addition to the brain, we found that diabetes was causally 25 related to a higher percent of liver fat ($\beta > 0.04$, $P < 2.75 \times 10^{-5}$, 5/8 MR methods significant) and increased pancreas fat (β > 0.5, P < 9.14×10⁻⁵, 5/8 MR methods significant). 26 27 Furthermore, we found some autoimmune, rheumatic and infectious diseases were causally associated with lower levels of liver iron content (β < -0.04, P < 4.47×10⁻⁴, >6/8 28 29 MR methods significant) and larger spleen volume ($\beta > 0.06$, $P < 4.47 \times 10^{-4}$, 6/8 MR 30 methods significant) (Figs. 4A-C).

31

1 Next, we evaluated the opposite direction with abdominal imaging traits as exposure 2 variables and multi-organ diseases as outcomes. At an FDR 5% level ($P < 1.40 \times 10^{-3}$), we 3 identified 44 significant pairs, with heart-related diseases occupying 15 among them, 4 followed by endocrine, nutritional metabolic disorders (10/44), disease of the respiratory 5 system (4/44), blood and blood-forming (4/44), musculoskeletal and connective (4/44), 6 and digestive system (4/44). The liver imaging traits were again the most frequent (35/44). 7 For example, a higher percent of liver fat had causal effects on multiple heart-related 8 diseases, such as angina pectoris, coronary angioplasty, coronary atherosclerosis, 9 ischemic heart disease (wide definition), myocardial infarction (strict), as well as heart 10 failure and coronary heart disease (β > 0.13, P < 1.40×10⁻³, 5/8 MR methods significant). 11 Further, an enlarged spleen volume was linked to an increased risk of cardiovascular 12 diseases, such as diseases of arteries, arterioles and capillaries ($\beta > 0.25$, $P < 1.12 \times 10^{-3}$, 13 5/8 MR methods significant). Beyond cardiovascular impacts, increased liver iron content 14 significantly elevated the risk of anemias, particularly iron deficiency anemia ($\beta > 0.19$, P 15 $< 9.80 \times 10^{-4}$, 5/8 MR methods significant). A causal relationship was observed between 16 higher percent of liver fat and liver diseases ($\beta > 0.13$, $P < 1.40 \times 10^{-3}$, 8/8 MR methods 17 significant), increased visceral adipose tissue volume and hernia of abdominal wall (β > 0.72, $P < 1.40 \times 10^{-3}$, 6/8 MR methods significant), as well as spleen volume and 18 19 noninfective enteritis and colitis ($\beta > 0.13$, $P < 9.66 \times 10^{-4}$, 5/8 MR methods significant). 20 Moreover, visceral adipose tissue volume led to an increased risk of asthma and chronic 21 lower respiratory diseases (β > 0.30, P < 1.10×10⁻³, 5/8 MR methods significant) (Fig. 4D).

22

23 Causal genetic links between skeleton DXA traits and clinical outcomes

24 The skeletal system serves as the foundational support for the human body, and as such, 25 skeletal abnormalities could potentially contribute to the risk of multi-organ diseases. We 26 identified 8 causal pairs at an FDR 5% level ($P < 1.04 \times 10^{-4}$), spanning conditions related to 27 both the circulatory system and the musculoskeletal and connective tissue. Notably, an 28 extended torso length was linked to an increased risk of several cardiovascular conditions, 29 such as coronary atherosclerosis and myocardial infarction ($|\beta|$ >18.72, P < 1.40×10⁻³, 5/8 30 MR methods significant). Furthermore, longer torso length was inked to several 31 musculoskeletal and connective tissue disorders, such as internal derangement of the 32 knee and meniscus derangement ($|\beta|>21.20$, $P < 1.49 \times 10^{-5}$, 5/8 MR methods significant)

1 (Fig. 5A). We also uncovered potential causal effects of multiple organ diseases on DXA-2 derived skeleton traits. At an FDR 5% level ($P < 1.04 \times 10^{-4}$), we found 4 significant results 3 that mainly on connective tissue disorders. For example, systemic connective tissue 4 disorders and other systemic involvement of connective tissue were associated with 5 lower average tibia height ($|\beta| > 0.0005$, $P < 3.61 \times 10^{-5}$, 5/8 MR methods significant) (Fig. 6 5B and Table S6).

7

8 **Discussion**

9 Observational studies have identified numerous links between imaging-derived 10 phenotypes and clinical outcomes. However, these associations are often influenced by 11 residual confounding, complicating the accurate inference of causal effect sizes⁶². MR 12 allows for the inference of causal relationships between exposure and outcome variables. 13 MR leverages the natural and random assortment of genetic variants during meiosis, 14 making these variants ideal instrumental variables for discerning causal effects. In the 15 present study, we evaluated the causal links between 402 multi-organ imaging traits and 16 clinical outcomes through bidirectional MR. To circumvent the issue of sample overlap⁶³, 17 which can bias the causal effect and has been overlooked in many current MR-based 18 studies, we used a two-sample MR design and sourced our imaging and clinical data from 19 different large-scale cohorts.

20

21 The interconnected nature of our organ systems suggested that diseases often affect 22 more than one part of the human body^{35,36,61,64}. The brain and heart are particularly 23 critical, with the brain controlling a variety of functions, including reactions, emotions, 24 vision, memory, and cognition^{65,66}, while the heart acts pumps oxygen and nutrient-rich 25 blood to other organs. Dysfunctions in various organs can potentially have detrimental 26 effects on the brain and heart, and vice versa. Besides connections to the brain and heart, 27 we also uncovered many other causal relationships across different organs. In this causal 28 discovery research, we implemented stringent criteria for selecting significant causal pairs 29 (Methods), with the goal being to ensure that all reported findings are statistically robust 30 and capable of offering potential biological insights. Consequently, the absence of certain 31 causal pairs in our study does not imply a lack of causal relationships. Moreover, our 32 findings should be interpreted carefully in the context of known biology. Whereas some

causal pairs are highly plausible and predictable based on current knowledge, many are
 novel and unexpected. These should stimulate further research to discern potential
 mechanistic pathways. A visualization of the interactions across different organ systems
 can be found in Figure 1B. We will discuss our findings in more detail below.

5

6 Intra-brain causal connections.

7 As expected, alterations in brain structure and function were found to be closely linked 8 with brain disorders, with some of these relationships appearing to be bidirectional. We 9 consistently identified causal connections between brain imaging traits and a variety of 10 psychiatric disorders or neurological diseases, such as Alzheimer's disease, dementia, 11 mood disorder, and sleep apnea. For example, AD and dementia had an impact on fMRI 12 traits, which were primarily observed as indicators of AD and dementia. Prior studies have 13 consistently reported that resting fMRI connectivity patterns are disrupted in patients 14 with Alzheimer's disease^{67,68}, particularly in brain regions involved in memory and 15 cognitive function^{69,70}. DTI abnormalities were found to be a precursor or an early sign of brain pathology that could lead to brain-related disorders^{71,72}. 16

17

18 Brain-heart causal connections.

19 Despite the increasing number of association studies investigating the brain-heart 20 interaction^{40,73}, causal genetic links within these systems remain largely uncharted. In this 21 study, we identified causal connections from hypertension to DTI parameters in multiple 22 white matter tracts, including the SCR, BCC, and GCC. Additionally, hypertension had 23 causal effects on regional brain volumes and fMRI traits, such as the mean activity within the orbito-affective network. These results could be attributed to the effects of 24 hypertension on cerebral small vessel health^{74,75}, leading to microvascular damage, which 25 26 can disrupt white matter integrity, alter brain function observable in fMRI, and contribute 27 to changes in brain structure, such as reduced regional volumes. Furthermore, elevated 28 blood pressure may cause ischemia and impair the blood-brain barrier, contributing to neuroinflammation and neurodegeneration, reflected in these imaging traits⁷⁶⁻⁷⁹. Hence, 29 30 effective management of hypertension through lifestyle adjustments and medication 31 could help mitigate these adverse effects on the brain, which should be addressed in 32 future studies.

1

2 We observed that heart structural measures, such as regional myocardial-wall thickness, 3 exhibited potential causal effects on Alzheimer's disease. Based on current knowledge, 4 this connection does not seem to have clear underlying biologic plausibility, and should 5 be interpreted cautiously until further knowledge is available regarding the role of cardiac 6 abnormalities in the pathogenesis of Alzheimer's disease, which is at present incompletely understood^{80,81}. Causal connections were also detected from the brain to 7 8 the heart. We found that mental or degenerative neurological disorders can affect CMR 9 traits, such as mood disorder affecting regional myocardial-wall thickness. The reason 10 behind it may be related to the stress response, which can lead to increased levels of stress hormones such as cortisol and adrenaline^{82,83}. These hormones can cause an 11 12 increase in blood pressure and heart rate, leading to hypertrophy (thickening) of the 13 myocardial wall over time as the heart works harder to pump blood^{84,85}. Mood disorders 14 may also cause lifestyle changes (such as changes in dietary and physical activity patterns) 15 that have deleterious effects on blood pressure and vascular function. Inflammation may 16 also be involved, since mood disorders have been associated with increased levels of 17 systemic inflammation, which is a known risk factor for various forms of cardiovascular 18 disease^{86,87}.

19

20 Bidirectional connections between the brain and abdominal organs.

21 Brain disorders were found to influence multiple abdominal organs. For example, we 22 found that degenerative neurological diseases, such as Alzheimer's disease and dementia 23 may exert potential causal effects on several abdominal imaging traits, such as liver fat 24 and volume, visceral/abdominal subcutaneous adipose tissue volume, as well as lung 25 volume. Patients with Alzheimer's disease and dementia often require multiple 26 medications to manage symptoms, including antipsychotics, antidepressants, and 27 medications aimed at slowing cognitive decline. Some of these medications can have 28 hepatotoxic effects or interact with other drugs in ways that might impact liver function. 29 Regular monitoring through liver function tests is important for patients on long-term 30 medication regimens. Alzheimer's disease and dementia also might lead to systemic 31 inflammation⁸⁸, which has been linked to abnormal intermediary metabolism, a key 32 regulator of liver fat and function⁸⁹. The connection between neurological disorders and

adipose tissue volume might be related to reduced physical activity⁹⁰ and corticosteroid 1 2 medications⁹¹. The connection between Alzheimer's disease and lung phenotypes may be related to effects of neurological diseases on respiratory muscle weakness^{92,93}. This 3 4 weakness could subsequently influence lung volume and functionality. Similar to 5 Alzheimer's disease and dementia, sleep apnea could also affect liver and adipose tissue. 6 Whereas sleep apnea and liver/adipose tissue may have overlying common determinants, 7 such as obesity, insulin resistance, decreased physical activity, and abnormal dietary 8 patterns, sleep apnea may also impact various metabolic processes in its own right, which 9 could contribute to further insulin resistance and fat accumulation in the liver. In addition 10 to neurological diseases, our study revealed that alcohol use disorder can cause an 11 increase in liver fat percentage. It is well documented that individuals suffering from 12 alcohol use disorder are more prone to develop alcoholic fatty liver disease⁹⁴.

13

14 Conversely, brain imaging traits were causally affected by various diseases of other organs 15 or systems. For example, we found that asthma influenced regional brain volumes. 16 Interestingly, prior studies have demonstrated that individuals with asthma may have 17 diminished cognitive function, including impaired memory and attention, as well as changes in brain activity patterns during cognitive tasks^{95,96}. Anxiety, stress, and 18 19 depression, which are often experienced by individuals with asthma, can also result in 20 alterations to brain structure. Notably, autoimmune diseases (as defined by FinnGen²⁷) 21 impacted brain imaging traits, such as DTI parameters of the SCR. Multiple sclerosis, an 22 autoimmune disease affecting the central nervous system, can cause damage to the 23 myelin sheath that surrounds axons and can occur in various brain regions^{97,98}, including the internal capsule. This damage can disrupt neural connections passing through the 24 25 anterior limb, leading to symptoms such as weakness, spasticity, and difficulty with balance and coordination. In rare autoimmune diseases, such as neuromyelitis optica⁹⁹ 26 and autoimmune encephalitis, inflammation, and damage can occur in the brain. The 27 28 resulting neurological symptoms can vary based on the severity and location of the 29 damage^{100,101}. Additionally, autoimmune diseases causing systemic inflammation, such as rheumatoid arthritis and lupus, could potentially affect the brain¹⁰² and white matter 30 31 tracts^{103,104}. Chronic inflammation can lead to changes in the microstructure of white 32 matter tracts, resulting in alterations in neural connectivity and function^{105,106}.

1

2 Intra-heart causal connections.

Bidirectional causal relationships were observed between cardiovascular diseases and 3 4 CMR traits. Hypertension was found to causally influence several CMR traits across 5 different heart chambers and aorta regions. Conversely, alterations in CMR traits were 6 contribute causally to heart diseases. These findings are well-aligned with our current 7 understanding of the effects of hypertension on the heart. For example, hypertension can 8 cause changes in the heart's structure and function due to increased afterload, leading to 9 left ventricular hypertrophy and changes in left atrial size,^{107,108} which can in turn 10 contribute to the development of various complications, including atrial fibrillation, heart 11 failure, and stroke¹⁰⁹. Additionally, changes in cardiac structure might influence blood 12 pressure regulation, since from a hemodynamic standpoint, blood pressure is the direct 13 result of interactions between the cardiac pump and its coupled vascular load¹¹⁰.

14

15 Causal connections between the heart and abdominal organs.

16 Heart health was found to be causally linked with various multi-organ imaging traits or 17 diseases. For example, liver fat was linked to multiple heart-related diseases, such as 18 coronary atherosclerosis. This may be due to the key role of the liver in intermediary and 19 lipoprotein metabolism, both of which are known contributors to the pathogenesis of 20 atherosclerotic vascular disease. Additionally, heart failure was observed to cause an 21 increase in spleen volume. The latter could be due to venous stasis and venous 22 hypertension, which is a known consequence of heart failure. Indeed, increased venous 23 pressure can lead to spleen enlargement, a condition known as splenomegaly¹¹¹. 24 Conversely, we found larger spleen volume to exhibit a causal effect on heart failure, a 25 causal connection that is more difficult to interpret based on current knowledge, and 26 which should stimulate further research. The pancreas also had causal effects on the 27 cardiovascular system. For example, excess pancreas fat was associated with a higher risk 28 of developing deep vein thrombosis of the lower extremities and pulmonary embolism. 29 Pancreatic steatosis, a condition where fat accumulates in the pancreas, is linked with 30 several metabolic abnormalities, including insulin resistance and inflammation, which can 31 contribute to the development of cardiovascular diseases^{112,113}.

32

1 <u>Causal connections between metabolic disorders and multiple organs.</u>

2 Diabetes was found to have an adverse impact on heart structural variations in AAo, RV, 3 and LV. Multiple pathways may account for these causal associations, such as diabetic cardiomyopathy¹¹⁴, microvascular dysfunction^{115,116}, and metabolic disturbances¹¹⁷. 4 Diabetes can also affect the fat accumulation in the liver and pancreas. The liver plays a 5 6 crucial role in managing glucose and fat metabolism. In the face of insulin resistance, the 7 liver can accumulate fat, leading to non-alcoholic fatty liver disease. Insulin resistance 8 prompts the liver to increase glucose production, contributing to high blood sugar levels, 9 while also interfering with the liver's ability to process fat, leading to fat accumulation. 10 Fat accumulation is not limited to the liver; it can also occur in the pancreas. The pancreas 11 is sensitive to the metabolic changes induced by insulin resistance and obesity. Excess fat 12 within the pancreas may affect its function, particularly the insulin-producing beta cells. Studies suggest that fat accumulation in the pancreas can impair insulin secretion^{118,119}. 13 14 exacerbating the cycle of insulin resistance and beta-cell dysfunction seen in type 2 15 diabetes. Additionally, the excess fat (especially in the form of triglycerides) within the pancreas can lead to beta-cell dysfunction¹²⁰. This dysfunction further impairs the body's 16 17 ability to produce and regulate insulin effectively, worsening glucose control¹²¹⁻¹²³.

18

19 <u>Skeleton DXA traits.</u>

20 We found genetic causal connections between DXA-derived skeleton traits and multiple 21 organ diseases. MR typically reflects long-term effects rather than immediate impacts, 22 making it a highly suitable method to measure causal effects related to the skeletal 23 system. This is because skeletal traits are less prone to rapid modifications over short 24 periods. Skeletal traits were shown to be potentially causally affected by musculoskeletal 25 and connective disorders, which might have multiple pathways, such as altered bone 26 density¹²⁴, abnormal bone growth and formation, as well as inflammatory conditions. 27 Conversely, skeletal disorders could contribute to numerous organ diseases, with heart 28 conditions being the most prevalent in our analysis. However, the precise underlying 29 mechanisms of these potentially causal connection require further study.

30

31 *Limitations and conclusions.*

1 Our study has several limitations. First, our GWAS summary statistics were sourced from 2 publicly available databases. Thus, we could not evaluate the impact of unobserved 3 confounders, such as population stratification, on our results. Second, a common 4 limitation that most existing MR methods share is that they require several model 5 assumptions. This may result in model misspecifications and issues related to data heterogeneity when integrating data from different data resources¹²⁵. We have 6 7 systematically applied quality control measures and performed sensitivity analyses in our 8 study. Future research implementing more advanced MR methods may relax some of 9 these model assumptions^{126,127}. Furthermore, MR studies are designed to examine the 10 effects of lifetime exposure factors on outcomes, not interventions within a specified 11 period. As a result, our findings may be interpreted differently than the rigorous results 12 obtained from randomized controlled trials. Moreover, our findings have varying degrees 13 of biologic plausibility based on current knowledge. They should therefore be interpreted 14 accordingly, and reinterpreted as new mechanistic knowledge becomes available.

15

In conclusion, we used two-sample bidirectional MR analyses to comprehensively explore the multi-organ causal connections between 372 clinical outcomes and 402 imagederived phenotypes of various organ systems. Our results revealed robust genetic evidence supporting causal connections within and across multiple organs. These findings will be useful in understanding complex pathogenic mechanisms and will contribute to further mechanistic research and ultimately, to the early prediction and prevention of multi-organ diseases from a whole-body perspective.

23

24 METHODS

25 Methods are available in the *Methods* section.

26 Note: One supplementary table zip file are available.

27

28 ACKNOWLEDGEMENTS

Research reported in this publication was supported by the National Institute On Aging of the National Institutes of Health under Award Number RF1AG082938. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study has also been partially supported by

1 funding from the Wharton Dean's Research Fund, Analytics at Wharton, and Purdue 2 Statistics Department. Assistance for this project was also provided by the UNC 3 Intellectual and Developmental Disabilities Research Center (NICHD; P50 HD103573). This 4 research has been conducted using summary-level data from the UK Biobank study and 5 the FinnGen research project. We would like to thank the individuals who represented 6 themselves in the UK Biobank and FinnGen studies for their participation and the research 7 teams for their efforts in collecting, processing, and disseminating these datasets. We 8 would like to thank the research computing groups at the University of North Carolina at 9 Chapel Hill, Purdue University, and the Wharton School of the University of Pennsylvania 10 for providing computational resources and support that have contributed to these 11 research results. 12 13 **AUTHOR CONTRIBUTIONS** 14 J.S. and B.Z. designed the study. J.S., C.C., B.L., Z. F., X.Y., Y.Y, X.W., and Y.L. analyzed the 15 data. R.Z. and J.C. helped interpret findings. B.X., T.L., and H.Z. provided feedback on the 16 results. J.S. and B.Z. wrote the manuscript with feedback from all authors. 17 18 COMPETING FINANCIAL INTERESTS 19 The authors declare no competing financial interests. 20 21 REFERENCES 22 1. Buckner, R.L., et al. Molecular, structural, and functional characterization of 23 Alzheimer's disease: evidence for a relationship between default activity, 24 amyloid, and memory. Journal of neuroscience 25, 7709-7717 (2005). 25 2. Pennell, D.J., et al. Clinical indications for cardiovascular magnetic resonance

- 26 (CMR): Consensus Panel report. *European heart journal* **25**, 1940-1965 (2004).
- Kun, E., *et al.* The genetic architecture and evolution of the human skeletal form.
 Science **381**, eadf8009 (2023).
- Petersen, S.E., *et al.* UK Biobank's cardiovascular magnetic resonance protocol.
 Journal of cardiovascular magnetic resonance **18**, 1-7 (2015).
- 5. Littlejohns, T.J., Sudlow, C., Allen, N.E. & Collins, R. UK Biobank: opportunities for
 cardiovascular research. *European heart journal* 40, 1158-1166 (2019).

1	6.	Miller, K.L., et al. Multimodal population brain imaging in the UK Biobank
2		prospective epidemiological study. Nature Neuroscience 19, 1523-1536 (2016).
3	7.	Thompson, P.M., et al. ENIGMA and global neuroscience: A decade of large-scale
4		studies of the brain in health and disease across more than 40 countries.
5		Translational psychiatry 10 , 1-28 (2020).
6	8.	Liu, Y., et al. Genetic architecture of 11 organ traits derived from abdominal MRI
7		using deep learning. <i>Elife</i> 10, e65554 (2021).
8	9.	Smith, S.M. & Nichols, T.E. Statistical challenges in "big data" human
9		neuroimaging. <i>Neuron</i> 97, 263-268 (2018).
10	10.	Tian, Y.E., et al. Heterogeneous aging across multiple organ systems and
11		prediction of chronic disease and mortality. Nature Medicine 29, 1221-1231
12		(2023).
13	11.	Taschler, B., Smith, S.M. & Nichols, T.E. Causal inference on neuroimaging data
14		with Mendelian randomisation. NeuroImage, 119385 (2022).
15	12.	Sanderson, E., et al. Mendelian randomization. Nature Reviews Methods Primers
16		2 , 1-21 (2022).
17	13.	Pingault, JB., et al. Using genetic data to strengthen causal inference in
18		observational research. Nature Reviews Genetics 19, 566-580 (2018).
19	14.	Aung, N., et al. Genome-wide analysis of left ventricular image-derived
20		phenotypes identifies fourteen loci associated with cardiac morphogenesis and
21		heart failure development. Circulation 140, 1318-1330 (2019).
22	15.	Córdova-Palomera, A., et al. Cardiac Imaging of Aortic Valve Area From 34 287
23		UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic
24		Comorbidity With Multiple Disease Phenotypes. Circulation: Genomic and
25		<i>Precision Medicine</i> 13 , e003014 (2020).
26	16.	Meyer, H.V., et al. Genetic and functional insights into the fractal structure of the
27		heart. <i>Nature</i> 584 , 589-594 (2020).
28	17.	Pirruccello, J.P., et al. Analysis of cardiac magnetic resonance imaging in 36,000
29		individuals yields genetic insights into dilated cardiomyopathy. Nature
30		<i>communications</i> 11 , 1-10 (2020).
31	18.	Pirruccello, J.P., et al. Genetic analysis of right heart structure and function in
32		40,000 people. <i>Nature genetics</i> 54 , 792-803 (2022).

1	19.	Thanaj, M., et al. Genetic and environmental determinants of diastolic heart
2		function. <i>Nature cardiovascular research</i> 1 , 361-371 (2022).
3	20.	Elliott, L.T., et al. Genome-wide association studies of brain imaging phenotypes
4		in UK Biobank. <i>Nature 562,</i> 210-216 (2018).
5	21.	Zhao, B., et al. Genome-wide association analysis of 19,629 individuals identifies
6		variants influencing regional brain volumes and refines their genetic co-
7		architecture with cognitive and mental health traits. Nature genetics 51, 1637-
8		1644 (2019).
9	22.	Smith, S.M., et al. An expanded set of genome-wide association studies of brain
10		imaging phenotypes in UK Biobank. <i>Nature neuroscience</i> 24 , 737-745 (2021).
11	23.	Zhao, B., et al. Common genetic variation influencing human white matter
12		microstructure. Science 372, eabf3736 (2021).
13	24.	Grasby, K.L., et al. The genetic architecture of the human cerebral cortex. Science
14		367 , eaay6690 (2020).
15	25.	Zhao, B., et al. Genetic influences on the intrinsic and extrinsic functional
16		organizations of the cerebral cortex. <i>medRxiv</i> , 2021.2007. 2027.21261187
17		(2021).
18	26.	Watanabe, K., et al. A global overview of pleiotropy and genetic architecture in
19		complex traits. <i>Nature genetics</i> 51 , 1339-1348 (2019).
20	27.	Kurki, M.I., et al. FinnGen provides genetic insights from a well-phenotyped
21		isolated population. <i>Nature</i> 613 , 508-518 (2023).
22	28.	Flynn, B.I., et al. Deep learning based phenotyping of medical images improves
23		power for gene discovery of complex disease. <i>medRxiv</i> , 2023.2003.
24		2007.23286909 (2023).
25	29.	Guo, J., et al. Mendelian randomization analyses support causal relationships
26		between brain imaging-derived phenotypes and risk of psychiatric disorders.
27		Nature Neuroscience 25 , 1519-1527 (2022).
28	30.	Chen, X., et al. Kidney damage causally affects the brain cortical structure: a
29		Mendelian randomization study. EBioMedicine 72, 103592 (2021).
30	31.	Williams, J.A., et al. Inflammation and brain structure in schizophrenia and other
31		neuropsychiatric disorders: a Mendelian randomization study. JAMA psychiatry
32		79 , 498-507 (2022).

1	22	Taniusla A stal Associations between mederate clashel consumption brain
1	32.	Topiwala, A., et al. Associations between moderate alcohol consumption, brain
2		iron, and cognition in UK Biobank participants: observational and mendelian
3		randomization analyses. PLoS medicine 19 , e1004039 (2022).
4	33.	Holmes, M.V., et al. Mendelian randomization of blood lipids for coronary heart
5		disease. <i>European heart journal</i> 36 , 539-550 (2015).
6	34.	Lamina, C. & Kronenberg, F. Estimation of the required lipoprotein (a)-lowering
7		therapeutic effect size for reduction in coronary heart disease outcomes: a
8		Mendelian randomization analysis. JAMA cardiology 4 , 575-579 (2019).
9	35.	Skou, S.T., et al. Multimorbidity. Nature Reviews Disease Primers 8 , 48 (2022).
10	36.	Langenberg, C., Hingorani, A.D. & Whitty, C.J. Biological and functional
11		multimorbidity—from mechanisms to management. Nature Medicine 29, 1649-
12		1657 (2023).
13	37.	Sudlow, C., et al. UK biobank: an open access resource for identifying the causes
14		of a wide range of complex diseases of middle and old age. PLoS medicine 12,
15		e1001779 (2015).
16	38.	Bijsterbosch, J., et al. Investigations into within-and between-subject resting-
17		state amplitude variations. Neuroimage 159, 57-69 (2017).
18	39.	Bai, W., et al. A population-based phenome-wide association study of cardiac
19		and aortic structure and function. Nature Medicine 26, 1654-1662 (2020).
20	40.	Zhao, B., et al. Heart-brain connections: Phenotypic and genetic insights from
21		magnetic resonance images. <i>Science</i> 380 , abn6598 (2023).
22	41.	Bowden, J., et al. A framework for the investigation of pleiotropy in two-sample
23		summary data Mendelian randomization. Statistics in medicine 36, 1783-1802
24		(2017).
25	42.	Burgess, S., Butterworth, A. & Thompson, S.G. Mendelian randomization analysis
26		with multiple genetic variants using summarized data. Genetic epidemiology 37,
27		658-665 (2013).
28	43.	Bowden, J., et al. Improving the accuracy of two-sample summary-data
29		Mendelian randomization: moving beyond the NOME assumption. Int J
30		Epidemiol 48 , 728-742 (2019).
-		

1	44.	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
2		instruments: effect estimation and bias detection through Egger regression.
3		International journal of epidemiology 44 , 512-525 (2015).
4	45.	Hartwig, F.P., Davey Smith, G. & Bowden, J. Robust inference in summary data
5		Mendelian randomization via the zero modal pleiotropy assumption.
6		International journal of epidemiology 46 , 1985-1998 (2017).
7	46.	Bowden, J., Davey Smith, G., Haycock, P.C. & Burgess, S. Consistent estimation in
8		Mendelian randomization with some invalid instruments using a weighted
9		median estimator. <i>Genetic epidemiology</i> 40 , 304-314 (2016).
10	47.	Ye, T., Shao, J. & Kang, H. Debiased inverse-variance weighted estimator in two-
11		sample summary-data Mendelian randomization. The Annals of statistics 49,
12		2079-2100 (2021).
13	48.	Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D.S. Statistical inference in
14		two-sample summary-data Mendelian randomization using robust adjusted
15		profile score. The Annals of Statistics 48, 1742-1769 (2020).
16	49.	Wang, J., et al. Causal inference for heritable phenotypic risk factors using
17		heterogeneous genetic instruments. <i>PLoS genetics</i> 17 , e1009575 (2021).
18	50.	Bennett, I.J., Madden, D.J., Vaidya, C.J., Howard, D.V. & Howard Jr, J.H. Age-
19		related differences in multiple measures of white matter integrity: A diffusion
20		tensor imaging study of healthy aging. <i>Human brain mapping</i> 31 , 378-390
21		(2010).
22	51.	Segmentation, A.H.A.W.G.o.M., et al. Standardized myocardial segmentation and
23		nomenclature for tomographic imaging of the heart: a statement for healthcare
24		professionals from the Cardiac Imaging Committee of the Council on Clinical
25		Cardiology of the American Heart Association. <i>Circulation</i> 105 , 539-542 (2002).
26	52.	Stratos, C., Stefanadis, C., Kallikazaros, I., Boudoulas, H. & Toutouzas, P.
27		Ascending aorta distensibility abnormalities in hypertensive patients and
28		response to nifedipine administration. The American journal of medicine 93, 505-
29		512 (1992).
30	53.	Asmar, R., et al. Aortic distensibility in normotensive, untreated and treated
31		hypertensive patients. <i>Blood pressure</i> 4 , 48-54 (1995).

1	54.	Nabati, M., Namazi, S.S., Yazdani, J. & Sharif Nia, H. Relation between aortic
2		stiffness index and distensibility with age in hypertensive patients. International
3		journal of general medicine, 297-303 (2020).
4	55.	Berman, M.N., Tupper, C. & Bhardwaj, A. Physiology, Left Ventricular Function.
5		(2019).
6	56.	Kim, DY. & Camilleri, M. Serotonin: a mediator of the brain–gut connection.
7		Official journal of the American College of Gastroenterology ACG 95 , 2698-2709
8		(2000).
9	57.	Jones, M., Dilley, J., Drossman, D. & Crowell, M. Brain–gut connections in
10		functional GI disorders: anatomic and physiologic relationships.
11		Neurogastroenterology & Motility 18 , 91-103 (2006).
12	58.	Keefer, L., et al. A Rome working team report on brain-gut behavior therapies for
13		disorders of gut-brain interaction. Gastroenterology 162, 300-315 (2022).
14	59.	Xie, Z., Tong, S., Chu, X., Feng, T. & Geng, M. Chronic kidney disease and
15		cognitive impairment: The kidney-brain axis. <i>Kidney Diseases</i> 8 , 275-285 (2022).
16	60.	de Donato, A., Buonincontri, V., Borriello, G., Martinelli, G. & Mone, P. The
17		dopamine system: insights between kidney and brain. Kidney and Blood Pressure
18		Research 47 , 493-505 (2022).
19	61.	McCracken, C., et al. Multi-organ imaging demonstrates the heart-brain-liver axis
20		in UK Biobank participants. Nature Communications 13, 7839 (2022).
21	62.	Walker, V.M., Zheng, J., Gaunt, T.R. & Smith, G.D. Phenotypic Causal Inference
22		Using Genome-Wide Association Study Data: Mendelian Randomization and
23		Beyond. Annu Rev Biomed Data Sci 5, 1-17 (2022).
24	63.	Burgess, S., Davies, N.M. & Thompson, S.G. Bias due to participant overlap in
25		two-sample Mendelian randomization. Genetic epidemiology 40, 597-608 (2016).
26	64.	Jaggi, A., et al. A structural heart-brain axis mediates the association between
27		cardiovascular risk and cognitive function. Imaging Neuroscience 2, 1-18 (2024).
28	65.	Berridge, K.C. & Kringelbach, M.L. Pleasure systems in the brain. Neuron 86, 646-
29		664 (2015).
30	66.	Bressler, S.L. & Menon, V. Large-scale brain networks in cognition: emerging
31		methods and principles. Trends Cogn Sci 14, 277-290 (2010).

1	67.	Wang, K., et al. Altered functional connectivity in early Alzheimer's disease: A
2	•••	resting-state fMRI study. <i>Human brain mapping</i> 28 , 967-978 (2007).
3	68.	Sorg, C., <i>et al.</i> Selective changes of resting-state networks in individuals at risk
4		for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences</i> 104 ,
5		18760-18765 (2007).
6	69.	Ranasinghe, K.G., <i>et al.</i> Regional functional connectivity predicts distinct
7		cognitive impairments in Alzheimer's disease spectrum. <i>NeuroImage: Clinical</i> 5,
8		385-395 (2014).
9	70.	Pini, L., et al. A low-dimensional cognitive-network space in Alzheimer's disease
10		and frontotemporal dementia. Alzheimer's Research & Therapy 14, 199 (2022).
11	71.	Torso, M., et al. In vivo cortical diffusion imaging relates to Alzheimer's disease
12		neuropathology. Alzheimers Res Ther 15 , 165 (2023).
13	72.	Tu, MC., et al. Joint diffusional kurtosis magnetic resonance imaging analysis of
14		white matter and the thalamus to identify subcortical ischemic vascular disease.
15		Scientific Reports 14 , 2570 (2024).
16	73.	Liu, W., et al. Brain-heart communication in health and diseases. Brain Research
17		Bulletin (2022).
18	74.	Walker, K.A., Power, M.C. & Gottesman, R.F. Defining the relationship between
19		hypertension, cognitive decline, and dementia: a review. Current hypertension
20		reports 19 , 1-16 (2017).
21	75.	Zhang, H., et al. Reduced regional gray matter volume in patients with chronic
22		obstructive pulmonary disease: a voxel-based morphometry study. American
23		Journal of Neuroradiology 34 , 334-339 (2013).
24	76.	Yang, C., Hawkins, K.E., Doré, S. & Candelario-Jalil, E. Neuroinflammatory
25		mechanisms of blood-brain barrier damage in ischemic stroke. American Journal
26		of Physiology-Cell Physiology 316 , C135-C153 (2019).
27	77.	Carnevale, D., et al. Role of neuroinflammation in hypertension-induced brain
28		amyloid pathology. <i>Neurobiology of aging</i> 33 , 205. e219-205. e229 (2012).
29	78.	Haspula, D. & Clark, M.A. Neuroinflammation and sympathetic overactivity:
30		Mechanisms and implications in hypertension. Autonomic Neuroscience 210, 10-
31		17 (2018).

1	79.	Sweeney, M.D., Sagare, A.P. & Zlokovic, B.V. Blood–brain barrier breakdown in
2		Alzheimer disease and other neurodegenerative disorders. Nature Reviews
3		Neurology 14 , 133-150 (2018).
4	80.	Niedermeyer, E. Alzheimer disease: caused by primary deficiency of the cerebral
5		blood flow. Clinical EEG and neuroscience 37 , 175-177 (2006).
6	81.	Kisler, K., Nelson, A.R., Montagne, A. & Zlokovic, B.V. Cerebral blood flow
7		regulation and neurovascular dysfunction in Alzheimer disease. Nature Reviews
8		Neuroscience 18, 419-434 (2017).
9	82.	Chu, B., Marwaha, K., Sanvictores, T. & Ayers, D. Physiology, stress reaction. in
10		StatPearls [Internet] (StatPearls Publishing, 2021).
11	83.	Charmandari, E., Tsigos, C. & Chrousos, G. Endocrinology of the stress response.
12		Annu. Rev. Physiol. 67 , 259-284 (2005).
13	84.	Colao, A., Marzullo, P., Di Somma, C. & Lombardi, G. Growth hormone and the
14		heart. Clinical endocrinology 54, 137-154 (2001).
15	85.	Fazio, S., et al. Growth hormone and heart performance: a novel mechanism of
16		cardiac wall stress regulation in humans. European Heart Journal 18, 340-347
17		(1997).
18	86.	Black, P.H. & Garbutt, L.D. Stress, inflammation and cardiovascular disease.
19		Journal of psychosomatic research 52 , 1-23 (2002).
20	87.	Libby, P. Inflammation and cardiovascular disease mechanisms. The American
21		journal of clinical nutrition 83 , 456S-460S (2006).
22	88.	Holmes, C. Systemic inflammation and A lzheimer's disease. Neuropathology and
23		applied neurobiology 39 , 51-68 (2013).
24	89.	Laleman, W., Claria, J., Van der Merwe, S., Moreau, R. & Trebicka, J. Systemic
25		inflammation and acute-on-chronic liver failure: too much, not enough.
26		Canadian Journal of Gastroenterology and Hepatology 2018 (2018).
27	90.	Scherder, E.J., Bogen, T., Eggermont, L.H., Hamers, J.P. & Swaab, D.F. The more
28		physical inactivity, the more agitation in dementia. Int Psychogeriatr 22, 1203-
29		1208 (2010).
30	91.	Peckett, A.J., Wright, D.C. & Riddell, M.C. The effects of glucocorticoids on
31		adipose tissue lipid metabolism. <i>Metabolism</i> 60, 1500-1510 (2011).

1	92.	Polkey, M.I., Lyall, R.A., Moxham, J. & Leigh, P.N. Respiratory aspects of
2		neurological disease. Journal of Neurology, Neurosurgery & Psychiatry 66, 5-15
3		(1999).
4	93.	Pollock, R.D., Rafferty, G.F., Moxham, J. & Kalra, L. Respiratory muscle strength
5		and training in stroke and neurology: a systematic review. International Journal
6		of Stroke 8 , 124-130 (2013).
7	94.	Kushner, T. & Cafardi, J. Chronic liver disease and COVID-19: alcohol use
8		disorder/alcohol-associated liver disease, nonalcoholic fatty liver
9		disease/nonalcoholic steatohepatitis, autoimmune liver disease, and
10		compensated cirrhosis. Clinical Liver Disease 15, 195 (2020).
11	95.	Rhyou, HI. & Nam, YH. Association between cognitive function and asthma in
12		adults. Annals of Allergy, Asthma & Immunology 126 , 69-74 (2021).
13	96.	Ray, M., Sano, M., Wisnivesky, J.P., Wolf, M.S. & Federman, A.D. Asthma control
14		and cognitive function in a cohort of elderly adults. Journal of the American
15		Geriatrics Society 63 , 684-691 (2015).
16	97.	Alvarez, J.I., Cayrol, R. & Prat, A. Disruption of central nervous system barriers in
17		multiple sclerosis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of
18		Disease 1812 , 252-264 (2011).
19	98.	Krupp, L.B., et al. International Pediatric Multiple Sclerosis Study Group criteria
20		for pediatric multiple sclerosis and immune-mediated central nervous system
21		demyelinating disorders: revisions to the 2007 definitions. Multiple Sclerosis
22		Journal 19 , 1261-1267 (2013).
23	99.	Huda, S., et al. Neuromyelitis optica spectrum disorders. Clinical Medicine 19,
24		169 (2019).
25	100.	Kim, W., Kim, SH., Huh, SY. & Kim, H.J. Brain abnormalities in neuromyelitis
26		optica spectrum disorder. Multiple sclerosis international 2012(2012).
27	101.	Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. Journal
28		of Clinical Neurology 12 , 1-13 (2016).
29	102.	Wartolowska, K., et al. Structural changes of the brain in rheumatoid arthritis.
30		Arthritis & Rheumatism 64 , 371-379 (2012).

103.	Kozora, E. & Filley, C.M. Cognitive dysfunction and white matter abnormalities in
	systemic lupus erythematosus. Journal of the International Neuropsychological
	Society 17 , 385-392 (2011).
104.	Appenzeller, S., et al. Longitudinal analysis of gray and white matter loss in
	patients with systemic lupus erythematosus. Neuroimage 34 , 694-701 (2007).
105.	Rosenberg, G.A. Inflammation and white matter damage in vascular cognitive
	impairment. <i>Stroke</i> 40 , S20-S23 (2009).
106.	Raj, D., et al. Increased white matter inflammation in aging-and Alzheimer's
	disease brain. Frontiers in molecular neuroscience 10, 206 (2017).
107.	Gerdts, E., et al. Correlates of left atrial size in hypertensive patients with left
	ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in
	Hypertension (LIFE) Study. Hypertension 39 , 739-743 (2002).
108.	Eshoo, S., Ross, D.L. & Thomas, L. Impact of mild hypertension on left atrial size
	and function. Circulation: Cardiovascular Imaging 2, 93-99 (2009).
109.	Sanfilippo, A.J., et al. Atrial enlargement as a consequence of atrial fibrillation. A
	prospective echocardiographic study. <i>Circulation</i> 82, 792-797 (1990).
110.	Saheera, S. & Krishnamurthy, P. Cardiovascular Changes Associated with
	Hypertensive Heart Disease and Aging. Cell Transplant 29, 963689720920830
	(2020).
111.	Hiraiwa, H., et al. Clinical significance of spleen size in patients with heart failure.
	<i>European Heart Journal</i> 42 , ehab724. 0756 (2021).
112.	Ormazabal, V., et al. Association between insulin resistance and the
	development of cardiovascular disease. Cardiovascular diabetology 17, 1-14
	(2018).
113.	Shah, A., Mehta, N. & Reilly, M.P. Adipose inflammation, insulin resistance, and
	cardiovascular disease. Journal of Parenteral and Enteral Nutrition 32, 638-644
	(2008).
114.	Boudina, S. & Abel, E.D. Diabetic cardiomyopathy, causes and effects. Reviews in
	Endocrine and Metabolic Disorders 11 , 31-39 (2010).
115.	Horton, W.B. & Barrett, E.J. Microvascular dysfunction in diabetes mellitus and
	cardiometabolic disease. Endocrine reviews 42, 29-55 (2021).
	 104. 105. 106. 107. 108. 109. 110. 111. 111. 111. 111. 111. 111. 111.

1	116.	Kibel, A., et al. Coronary microvascular dysfunction in diabetes mellitus. Journal
2		of International Medical Research 45 , 1901-1929 (2017).
3	117.	Fuentes-Antrás, J., et al. Targeting metabolic disturbance in the diabetic heart.
4		Cardiovascular Diabetology 14 , 1-11 (2015).
5	118.	Wagner, R., et al. Metabolic implications of pancreatic fat accumulation. Nat Rev
6		Endocrinol 18 , 43-54 (2022).
7	119.	Yaney, G.C. & Corkey, B.E. Fatty acid metabolism and insulin secretion in
8		pancreatic beta cells. <i>Diabetologia</i> 46, 1297-1312 (2003).
9	120.	Dludla, P.V., et al. Pancreatic beta-cell dysfunction in type 2 diabetes:
10		Implications of inflammation and oxidative stress. World J Diabetes 14, 130-146
11		(2023).
12	121.	Kocaturk, E., Kar, E., Kusku Kiraz, Z. & Alatas, O. Insulin resistance and pancreatic
13		beta cell dysfunction are associated with thyroid hormone functions: A cross-
14		sectional hospital-based study in Turkey. Diabetes Metab Syndr 14, 2147-2151
15		(2020).
16	122.	Meeks, K.A.C., Adeyemo, A. & Agyemang, C. Beta-cell dysfunction and insulin
17		resistance in relation to abnormal glucose tolerance in African populations: can
18		we afford to ignore the diversity within African populations? BMJ Open Diabetes
19		Res Care 10 (2022).
20	123.	Bonora, E., et al. Insulin resistance and beta-cell dysfunction in newly diagnosed
21		type 2 diabetes: Expression, aggregation and predominance. Verona Newly
22		Diagnosed Type 2 Diabetes Study 10. <i>Diabetes Metab Res Rev</i> 38, e3558 (2022).
23	124.	Whalen, R., Carter, D. & Steele, C. Influence of physical activity on the regulation
24		of bone density. Journal of biomechanics 21 , 825-837 (1988).
25	125.	Zhao, Q., Wang, J., Spiller, W., Bowden, J. & Small, D.S. Two-sample instrumental
26		variable analyses using heterogeneous samples. Statistical Science 34, 317-333
27		(2019).
28	126.	Cui, R., et al. Improving fine-mapping by modeling infinitesimal effects. bioRxiv,
29		2022.2010. 2021.513123 (2022).
30	127.	Xue, H., Shen, X. & Pan, W. Causal Inference in Transcriptome-Wide Association
31		Studies with Invalid Instruments and GWAS Summary Data. Journal of the
32		American Statistical Association, 1-27 (2023).

1	128.	Tseng, W.Y., Su, M.Y. & Tseng, Y.H. Introduction to Cardiovascular Magnetic
2		Resonance: Technical Principles and Clinical Applications. Acta Cardiol Sin 32,
3		129-144 (2016).
4	129.	Pennell, D.J. Cardiovascular magnetic resonance. Circulation 121, 692-705
5		(2010).
6	130.	Bai, W., et al. Automated cardiovascular magnetic resonance image analysis with
7		fully convolutional networks. Journal of Cardiovascular Magnetic Resonance 20,
8		1-12 (2018).
9	131.	Bai, W., et al. Recurrent neural networks for aortic image sequence
10		segmentation with sparse annotations. International conference on medical
11		image computing and computer-assisted intervention, 586-594 (2018).
12	132.	Miller, K.L., et al. Multimodal population brain imaging in the UK Biobank
13		prospective epidemiological study. Nat Neurosci 19, 1523-1536 (2016).
14	133.	Zhao, B., et al. Heritability of regional brain volumes in large-scale neuroimaging
15		and genetic studies. Cerebral Cortex 29, 2904-2914 (2019).
16	134.	Zhao, B., et al. Large-scale GWAS reveals genetic architecture of brain white
17		matter microstructure and genetic overlap with cognitive and mental health
18		traits (n= 17,706). <i>Molecular psychiatry</i> 26 , 3943-3955 (2021).
19	135.	Avants, B.B., et al. A reproducible evaluation of ANTs similarity metric
20		performance in brain image registration. <i>Neuroimage</i> 54, 2033-2044 (2011).
21	136.	Jahanshad, N., et al. Multi-site genetic analysis of diffusion images and voxelwise
22		heritability analysis: A pilot project of the ENIGMA–DTI working group.
23		Neuroimage 81 , 455-469 (2013).
24	137.	Kochunov, P., et al. Multi-site study of additive genetic effects on fractional
25		anisotropy of cerebral white matter: comparing meta and megaanalytical
26		approaches for data pooling. <i>Neuroimage</i> 95 , 136-150 (2014).
27	138.	Glasser, M.F., et al. A multi-modal parcellation of human cerebral cortex. Nature
28		536 , 171-178 (2016).
29	139.	Ji, J.L., et al. Mapping the human brain's cortical-subcortical functional network
30		organization. Neuroimage 185, 35-57 (2019).

1 140. Bowden, J., et al. Improving the accuracy of two-sample summary-data

Mendelian randomization: moving beyond the NOME assumption. *International journal of epidemiology* 48, 728-742 (2019).

4

5 METHODS

6 Multi-organ imaging traits.

7 The imaging data were sourced from the UK Biobank (UKB) study, which enrolled 8 approximately 500,000 individuals aged between 40 and 69 from 2006 to 2010 9 (https://www.ukbiobank.ac.uk/). These multi-organ imaging data were collected from 10 the ongoing UKB imaging study project (https://www.ukbiobank.ac.uk/explore-your-11 participation/contribute-further/imaging-study), which aims to collect brain, heart, and 12 abdomen scans from 100,000 participants. Ethical approval for the UKB study was 13 secured from the North West Multicentre Research Ethics Committee (approval number: 14 11/NW/0382).

15

16 Studies of brain and heart diseases usually rely on magnetic resonance imaging (MRI) 17 scans, which are well-established clinical endophenotypes. Cardiovascular magnetic 18 resonance imaging (CMR) is a set of MRI techniques that are designed to assess 19 ventricular function, cardiovascular morphology, myocardial perfusion, and other cardiac 20 functional and structural features^{128,129}. They have been frequently used to reveal heartrelated issues clinically. The CMR traits used in the paper were originally generated from 21 22 the raw short-axis, long-axis, and aortic cine images using the state-of-the-art heart 23 imaging segmentation and feature representation framework^{39,130,131}. We divided the 24 generated 82 CMR traits into 6 categories. The first two are aortic sections, namely 25 ascending aorta (AAo) and descending aorta (DAo), which serve as the main 'pipe' in 26 supplying blood to the entire body. The other four are the global measures of 4 cardiac 27 chambers, including the left ventricle (LV), right ventricle (RV), left atrium (LA), and right 28 atrium (RA), which altogether manage the heartbeat and blood flow. There are also some 29 other traits, such as regional phenotypes of the left ventricle myocardial-wall thickness 30 and strain (Table S1). The summary-level GWAS data of these 82 CMR traits were 31 obtained from Zhao, et al. ⁴⁰.

32

Brain MRI provides detailed information about brain structure and function¹³², such as 1 2 abnormal growth, healthy aging, white matter diseases, structural issues, and functional 3 abnormalities. In this paper, the summary-level GWAS data were collected from recent 4 multi-modal image genetic studies, including regional brain volumes from structural 5 MRI^{21,133} (sMRI), diffusion tensor imaging (DTI) parameters from diffusion MRI^{23,134} (dMRI), and functional activity (that is, amplitude³⁸) and functional connectivity phenotypes from 6 resting functional MRI²⁵ (resting fMRI). In sMRI, we used ANTs¹³⁵ to generate regional 7 8 brain volumes for cortical and subcortical regions and global brain volume measures. In dMRI, we used the ENIGMA-DTI pipelines^{136,137} to generate tract-averaged parameters 9 10 for fractional anisotropy, mean diffusivity, axial diffusivity, radial diffusivity, and mode of 11 anisotropy in major white matter tracts and across the whole brain. For resting fMRI, we 12 extracted phenotypes from brain parcellation-based analysis. We used the Glasser360 atlas¹³⁸, which divided the cerebral cortex into 360 regions in 12 functional networks¹³⁹. 13 14 We considered 90 network-level resting fMRI phenotypes that evaluated interactions and 15 spontaneous neural activity at rest.

16

The 11 imaging traits from abdominal MRI were derived by Liu., et al⁸ using deep learning methods in terms of volume, fat, and iron in several organs and tissues, such as the liver, spleen, kidney, lung, pancreas, and adipose tissue. Skeleton DXA traits, including all long bone lengths as well as hip and shoulder width, were derived by Kun, et al. ³ using deep learning methods on whole-body DXA images. All eight skeleton traits have been controlled for height.

23

24 FinnGen clinical endpoints.

25 We used 372 clinical endpoints (304 with more than 10.000 cases and 68 more with at 26 least 5000 cases) collected by the FinnGen project, which were selected from the R9 27 release (https://www.finngen.fi/en/access results). Our initial criterion for selecting 28 diseases was to include those with more than 10,000 cases. For certain significant 29 diseases, such as Alzheimer's disease and neoplasm, we further relaxed the case number 30 cutoff to 5,000. The 372 clinical endpoints covered diseases from various categories, 31 namely, mental and behavioral disorders, diseases of the nervous system, diseases of the 32 eye and adnexa, diseases of the genitourinary system, diseases of the circulatory systems,

1 endocrine, nutritional and metabolic disorders, diseases marked as autoimmune origin, 2 diseases of the respiratory system, diseases of the digestive system, diseases of blood and 3 blood-forming, diseases of the musculoskeletal system and connective tissue, as well as 4 some other endpoints. The definitions can be found at https://risteys.finregistry.fi/. The 5 FinnGen data used in our study was obtained from separate cohorts than those supplying 6 imaging traits, which were derived from the UKB study, thus ensuring there was no 7 sample overlap. Detailed information of these 372 clinical variables can be found in Table 8 **S2**.

9

10 Mendelian randomization analysis.

11 We examined the genetic causal relationships between the 402 imaging traits (101 brain 12 regional volume traits, 110 brain DTI parameters, 90 network-level fMRI phenotypes, 82 13 CMR traits, 11 abdominal traits, and 8 skeleton DXA traits) and 372 clinical endpoints. 14 Prior to conducting the Mendelian randomization (MR) analysis, we conducted standard 15 preprocessing and quality control procedures. First, we selected genetic variants based on a significance threshold of 5×10⁻⁸ in the exposure GWAS data. To ensure the 16 17 independence of the genetic variants used in MR, we implemented LD clumping with a window size of 10,000 and an r² threshold of 0.01, using the 1000 Genomes European 18 19 ancestry data as a reference panel. We used the TwoSampleMR package 20 (https://mrcieu.github.io/TwoSampleMR/) for harmonization, which enabled us to 21 accurately align alleles between the selected variants in the exposure and the reported 22 effect on the outcome.

23

24 We assessed the performance of 8 MR methods, which included Inverse variance 25 weighted (fixed effect), Inverse variance weighted (multiplicative random effect), MR-26 Egger, Simple Median, Weighted Median, Weighted Mode, DIVW, GRAPPLE, and MR-RAPS^{41,42,44-49,140}, where MR Egger was used as the pleiotropy test and will not be included 27 28 in the figures. To ensure the reliability of our results, we implemented several quality 29 control procedures. We excluded causal estimates that relied on fewer than 6 genetic 30 variants, as a larger number of genetic variants increases the statistical power of MR 31 analysis^{47,48}. We retained causal pairs that were significant in at least two out of the eight 32 methods. We also screened for pleiotropy by using the MR-Egger intercept, the most used

1 method for testing the pleiotropy assumption. If a causal estimate failed the MR-Egger

2 intercept test, we required that it have significant results in at least one of the robust MR

3 methods, such as Weighted Median, Weighted Model, MR-RAPS, or GRAPPLE.

4 Additionally, we require all the selected causal pairs to be significant in more than half of

- 5 the methods.
- 6

7 Code availability

8 We made use of publicly available software and tools. Our analysis code will be made9 freely available at Zenodo.

10

11 Data availability

We used summary-level GWAS data in this study, which can be obtained from the FinnGen project (<u>https://www.finngen.fi/en/access_results</u>), BIG-KP (<u>https://bigkp.org/</u>), Heart-KP (<u>https://heartkp.org/</u>), and project-specific resources are detailed in Liu., et al ⁸ and Kun, et al. ³.

16

17 Figure legends

18 Fig. 1 Overview of study design and findings.

19 (A). An overview of our multi-organ imaging genetic study, investigating 372 clinical 20 outcomes. We used diverse imaging traits including multi-modal brain, cardiac, 21 abdominal, and skeletal DXA imaging to explore their relationships with the clinical 22 endpoints. Our study encompasses a comprehensive range of brain imaging modalities, 23 such as structural MRI, diffusion MRI, and resting-state fMRI. The cardiac imaging data 24 comprise short-axis, long-axis, and aortic cine images. Volume, iron content, and percent 25 fat were measured across 6 different abdominal organs and tissues, yielding in 11 image-26 derived abdominal phenotypes. Additionally, we included 8 skeleton imaging traits 27 encompassing long bone lengths as well as hip and shoulder width. (B). A high-level 28 summary of our bidirectional findings. The left panel displayed all the imaging traits that 29 have been used in the study. The grey arrow demonstrates the main findings, such as the 30 intra-brain, intra-heart, brain-heart, and brain-abdominal-organs causal connections. The 31 right panel depicts the intricate web of causal interactions among various organs as

1 uncovered in our study. The width of an arrow corresponds to the volume of findings

2 associated with it.

3

4 Fig. 2 Selected genetic causal effects of clinical outcomes on brain imaging traits.

5 We illustrated selected significant ($P < 1.31 \times 10^{-4}$) putative causal genetic links from 6 clinical endpoints (Exposure) to brain imaging traits (Outcome), with adjustment for 7 multiple testing using the FDR procedure. (A). The causal effect of degenerative 8 neurological diseases on brain imaging traits. (B). The causal effect of hypertension on 9 brain imaging traits. (C). The causal effect of other diseases on brain imaging traits. (D). The causal effect of brain imaging traits on degenerative neurological diseases. The term 10 11 'IDP Category' is used to signify the category of imaging traits, while '#IVs' stands for the 12 number of genetic variants utilized as instrumental variables. Various MR methods and 13 their associated regression coefficients are marked with different colors for easy 14 identification. See Table S1 for data resources on clinical endpoints and Table S2 for data 15 resources on imaging traits.

16

17 Fig. 3 Selected genetic causal effects between heart imaging traits and clinical endpoints.

18 (A). Selected significant ($P < 6.95 \times 10^{-4}$) causal genetic links from heart-related diseases 19 (Exposure) to heart imaging traits (Outcome) with adjustment for multiple testing using 20 the FDR procedure. (B). Selected significant ($P < 6.95 \times 10^{-4}$) causal genetic links from 21 metabolic disorders (Exposure) to heart imaging traits (Outcome) with adjustment for 22 multiple testing using the FDR procedure. (C). Selected significant ($P < 6.95 \times 10^{-4}$) causal 23 genetic links from brain disorders (Exposure) to heart imaging traits (Outcome) with 24 adjustment for multiple testing using the FDR procedure. (D). Selected significant (P < P25 6.95×10^{-4}) causal genetic links from heart imaging traits (Exposure) to heart-related 26 diseases (Outcome) with adjustment for multiple testing using the FDR procedure. (E). 27 Selected significant ($P < 6.95 \times 10^{-4}$) causal genetic links from heart imaging traits 28 (Exposure) to Alzheimer's disease (Outcome) with adjustment for multiple testing using 29 the FDR procedure. The term 'IDP Category' is used to signify the category of imaging 30 traits, while '#IVs' stands for the number of genetic variants utilized as instrumental 31 variables. Various MR methods and their associated regression coefficients are marked

with different colors for easy identification. (F). A high-level summary of our findings. See
 Table S1 for data resources of clinical endpoints and Table S2 for data resources on

- 3 imaging traits.
- 4

5 Fig. 4 Selected genetic causal effects between abdominal imaging traits and clinical 6 endpoints.

7 (A) Selected significant ($P < 1.40 \times 10^{-3}$) causal genetic links from clinical endpoints 8 (Exposure) to liver imaging traits (Outcome) with adjustment for multiple testing using 9 the FDR procedure. (B). Selected significant ($P < 1.40 \times 10^{-4}$) causal genetic links from clinical endpoints (Exposure) to pancreas imaging traits (Outcome) with adjustment for 10 11 multiple testing using the FDR procedure. (C). Selected significant ($P < 1.40 \times 10^{-3}$) causal 12 genetic links from clinical endpoints (Exposure) to spleen imaging traits (Outcome) with adjustment for multiple testing using the FDR procedure. (D). Selected significant (P < 13 14 1.40×10^{-4}) causal genetic links from liver imaging traits (Exposure) to pancreas clinical 15 endpoints (Outcome) with adjustment for multiple testing using the FDR procedure. The 16 term 'IDP Category' is used to signify the category of imaging traits, while '#IVs' stands for 17 the number of genetic variants utilized as instrumental variables. Various MR methods 18 and their associated regression coefficients are marked with different colors for easy 19 identification. (E). A high-level summary of our bidirectional findings. See Table S1 for 20 data resources on clinical endpoints and **Table S2** for data resources on imaging traits.

21

Fig. 5 Selected genetic causal effects between skeleton imaging traits and clinicalendpoints.

We illustrated selected significant ($P < 1.04 \times 10^{-4}$) causal genetic links from (**A**) skeleton imaging traits (Exposure) to clinical endpoints (Outcome) with adjustment for multiple testing using the FDR procedure and (**B**) clinical endpoints (Exposure) to skeleton imaging traits (Outcome). The term 'IDP Category' is used to signify the category of imaging traits, while '#IVs' stands for the number of genetic variants utilized as instrumental variables. Various MR methods and their associated regression coefficients are marked with different colors for easy identification. The skeleton diagram on the right shows the region

- 1 of the corresponding IDP. See **Table S1** for data resources on clinical endpoints and **Table**
- 2 **S2** for data resources on imaging traits.

3




Figure 1

	Exposure	IDP Category	Outcome	#IVs	Estimates
	Dementia	fMRI	Default mode network	29	
	Dementia	ŤIV/IRI	unctional connectivity f default mode network	29	
	Dementia	fMRI	Dorsal attention network	29	
	Dementia	fMRI	Frontoparietal network	29	
Alzł	neimer's disease	fMRI	Default mode network	24	
Alzł	neimer's disease	fMRI	Dorsal attention network	24	
Alzł	neimer's disease	fMRI	Frontoparietal network	24	
В					-0.12 -0.08 -0.04 0
	Exposure	IDP Category	Outcome	#IVs	Estimates
	Hypertension	DTI	BCC (FA)	230	IVW (fixed)
	Hypertension	DTI	GCC (FA)	230	Median-based
	Hypertension		unctional connectivity of orbito-affective network	230	GRAPPLE
	Hypertension	DTI	SCR (RD)	230	
	Hypertension	Brain regional volume	Grey matter	230	**************************************
С					-0.2 -0.1 0 0.1 0.2
-	Exposure	IDP Category	Outcome	#IVs	Estimates
	Allergic asthma	Regional brain volume	n Right inferior lateral ventricle	24	
	Autoimmune diseases	DTI	GCC (FA)	74	
	Autoimmune diseases	fMRI	Cingulo-opercular network	73	
כ					-0.16 -0.12 -0.08 -0.04 0 0.04
	Exposure	IDP Category	y Outcome	#IVs	Estimates
	BCC	DTI	Dementia	13	
	GCC	DTI	Dementia	21	

Figure 2

Α							D					
Exposure II	DP Categor	/ Outcome	#IVs		E	stimates	Exposure	IDP Categ	ory	Outcome	#IVs	Estimates
Cardiac arrhythmias	LA	Left atrium ejection fraction	58		_ <u>‡</u>		Ascending aorta maximum area		D arte	iseases of arteries, prioles and capillaries	47	<u> </u>
Cardiovascular diseases	DAo	Descending aorta distensibility	65	-	-		Descending aor maximum area	DAO	bi	ders of ocular muscle nocular movement, modation and refracti	25	
Cardiovascular diseases	LV	Global radial strain	65				Left ventricula ejection fractio	n LV		Heart failure	6	
Cardiovascular diseases	LA	Left atrium minimum volume	65				Regional myocard wall thickness segment 11	ial- LV		Paroxysmal tachycardia	12	
Atrial fibrillation and flutter	LA	Left atrium ejection fraction	97		4		Regional myocard wall thickness segment 16	ial- LV		Hypertension	9	
Heart failure	LA	Left atrium ejection fraction	6	=			Right ventricula ejection fractio			Other heart diseases	6	
Hypertensive heart disease	LV	Left ventricular myocardial mass	9			1	E				-1.0	-0.8 -0.8 -0.4 -0.2 0.0 0.2 0.4 0.6 0
Hypertension	AAo	Ascending aorta distensibility	230				Exposure Regional myocar wall thickness	dial-	ategory	Outcome	#IVs 6	Estimates
Hypertension	DAo	Descending aorta distensibility	230		-	_	segment 5					-1 -0.8 -0.6 -0.4 -0.2 0
Hypertension	LA	Left atrium ejection fraction	230				F			Descen	ding aorta	
в			-0.6	-0.4	-0.2	0 0.2	Ascen	ding aort				
	DP Categor	/ Outcome	#IVs		Estimates		-		٠		/ Pulm	onary arteries
Type 2 diabetes	AAo	Ascending aorta maximum area	177	#	-	IVW (fixed)	_	(Left atri	ium
Type 2 diabetes	LV 1	Global myocardial-wall hickness at end-diastole	177			Median-based Mode-based	_	X		\sim		
Type 2 diabetes	LV F	Regional myocardial-wall thickness segment6	177			MR RAPS	Right atrium				Myo	ocardial thickness
Pure sypercholesterolaem	nia LA	Left atrium stroke volume	28				-					
Hypothyroidism	LV	Regional radial strain 12	166		_		-		1			Hypertension Atrial fibrillation
Metabolic disorders	LA	Left atrium stroke volume	28				-		X	1		Cardiovascular diseases
с			-0.1		0	0.1 0).2 Diabi	/				 Heart failure Arrhythmia
-	DP Categor	y Outcome	#	#IVs	Estimate	5	_ Kigni	ventricle	:			 Dementia
Dementia	RV	Right ventricular end- diastolic volume			+		-			Left ventri	le	Alzheimer's diseases
Mood [affective] disorders	LV	Regional myocardial-wa thickness segment 12		16	-	<u> </u>	-					 Mood disorders Type 2 diabetes
Mood [affective] disorders	LV	Regional myocardial-wa thickness segment 8		16			-					Metabolic disorders

Figure 3

Α						D						
Exposure	IDP Category	Outcome	#IVs	Est	imates	Exposure	IDP Category	Outcome	#IVs		Estimates	
Type 2 diabetes	Liver	Liver volume	216	-	* * *	Liver iron content	Liver	Anaemias	12			
Other degenerative diseases of the nervous system	Liver	Liver volume	19	*****		Liver iron content	Liver	Iron deficiency anaemia	12			
Sleep apnoea	Liver	Percent liver fat	18	_		Liver iron content	Liver	Hyperlipidaemia	12	-	-	
Alzheimer's disease	Liver	Percent liver fat	28		IVW (fixed)	Liver iron content	Liver	Coxarthrosis	12			
Dementia	Liver	Percent liver fat	37		DIVW Median-based Mode-based	Liver volume	Liver	Type 2 diabetes	10			
Other degenerative diseases of the nervous system	Liver	Percent liver fat	19	ŧ		Percent liver fat	Liver	Type 2 diabetes	12			
Type 2 diabetes	Liver	Percent liver fat	216		+ + +	Percent liver fat	Liver	Pure hypercholesterolaemia	12	ŧ		
Diseases of liver	Liver	Percent liver fat	8	-	÷	Percent liver fat	Liver	Disorders of lipoprotein metabolism and other lipidaemias	12	-		
Autoimmune diseases	Liver	Liver iron content	79	ŧ		Percent liver fat	Liver	Metabolic disorders	12	+++	-	
Diabetic ketoacidosis	Liver	Liver iron content	63			Percent liver fat	Liver	Diseases of liver	12			
Diabetes, several complications	Liver	Liver iron content	36	===		E			4	0.4 -0.2	0 0.2 0.4 0.6 0.8	
Polyarthropathies	Liver	Liver iron content	38	ŧ			Liv	er		Demer	ntia	
Other arthritis (FG)	Liver	+			••				 Alzheimer's diseases Sleep apnoea 			
В			-0	.2	0 0.2 -0.4 0.6 0.8 1 1.2	D					diabetes	
Exposure	IDP Catego	ry Outcome	#IVs		Estimates	Pan	creas	0.0	1			
Type 2 diabetes	betes Pancreas Pancreas fa		216			Adipose tissue volume				 Metabolic disorders Hyperlipidaemia 		
с					-0.01 0.02 0.05 0.08	••				Anaem		
Exposure	IDP Catego	ory Outcome	#IV	s	Estimates	Kid	ney			😑 Obesit	,	
Obesity			30			•	een		$\langle $	 Disorders of digestive systems Disorders of respiratory systems 		
Other systemic involvement of connective tissue (F	G) Spleen	Spleen volume	14			•						

Figure 4




Figure 5